Brand U, Menge H G, Neumann B W, Stille G
Byk Gulden Pharmaceuticals, Konstanz, FRG.
Pharmacopsychiatry. 1989 Nov;22(6):255-7. doi: 10.1055/s-2007-1014610.
The study served to answer the question whether metabolites possibly contribute to the clinical actions of the neuroleptic drug perazine. The primary metabolites demethylperazine and perazine sulfoxide were investigated with regard to influences on behavior in mice, to an antiemetic action in dogs, and to a modification of the pressor effect of noradrenaline in rats. In contrast to perazine, none of the metabolites exhibited effects that can be interpreted to indicate neuroleptic or antidepressive properties of the compounds.
该研究旨在回答代谢物是否可能对神经安定药物奋乃静的临床作用有贡献这一问题。对主要代谢物去甲基奋乃静和奋乃静亚砜进行了研究,考察它们对小鼠行为的影响、对犬的止吐作用以及对大鼠去甲肾上腺素升压作用的改变。与奋乃静不同,这些代谢物均未表现出可解释为表明这些化合物具有神经安定或抗抑郁特性的作用。